context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. | text | 1.00 | percentItemType | text: <entity> 1.00 </entity> <entity type> percentItemType </entity type> <context> Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. | text | 2.00 | percentItemType | text: <entity> 2.00 </entity> <entity type> percentItemType </entity type> <context> Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. | text | 0.00 | percentItemType | text: <entity> 0.00 </entity> <entity type> percentItemType </entity type> <context> Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. | text | 1.75 | percentItemType | text: <entity> 1.75 </entity> <entity type> percentItemType </entity type> <context> Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. | text | 0.75 | percentItemType | text: <entity> 0.75 </entity> <entity type> percentItemType </entity type> <context> Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. | text | 0.10 | percentItemType | text: <entity> 0.10 </entity> <entity type> percentItemType </entity type> <context> Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. </context> | us-gaap:LineOfCreditFacilityCommitmentFeePercentage |
Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. | text | 0.30 | percentItemType | text: <entity> 0.30 </entity> <entity type> percentItemType </entity type> <context> Loans under the Prior Credit Agreement bear interest by reference, at our election, to the SOFR rate (subject to a 0.10 % per annum adjustment) or base rate, in each case subject to a 0 % floor. The applicable margin on SOFR rate loans varies from 1.00 % to 2.00 % and the applicable margin on base rate loans varies from 0.00 % to 1.00 %, in each case determined based on our credit rating. As of December 31, 2024, the applicable margin on SOFR rate loans was 1.75 % and the applicable margin on base rate loans was 0.75 %. A letter of credit fee is payable by us equal to the applicable margin for SOFR rate loans times the daily amount available to be drawn under outstanding letters of credit. The commitment fee rate payable to the lenders varies from 0.10 % to 0.30 % based on our credit rating. </context> | us-gaap:LineOfCreditFacilityCommitmentFeePercentage |
As of December 31, 2024, we had no borrowings outstanding under our revolving credit facility. We had $ 2.1 million in letters of credit outstanding under the Prior Credit Agreement at December 31, 2024 and, as a result, had available borrowing capacity of approximately $ 613 million at that date. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we had no borrowings outstanding under our revolving credit facility. We had $ 2.1 million in letters of credit outstanding under the Prior Credit Agreement at December 31, 2024 and, as a result, had available borrowing capacity of approximately $ 613 million at that date. </context> | us-gaap:LineOfCredit |
As of December 31, 2024, we had no borrowings outstanding under our revolving credit facility. We had $ 2.1 million in letters of credit outstanding under the Prior Credit Agreement at December 31, 2024 and, as a result, had available borrowing capacity of approximately $ 613 million at that date. | text | 2.1 | monetaryItemType | text: <entity> 2.1 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we had no borrowings outstanding under our revolving credit facility. We had $ 2.1 million in letters of credit outstanding under the Prior Credit Agreement at December 31, 2024 and, as a result, had available borrowing capacity of approximately $ 613 million at that date. </context> | us-gaap:LettersOfCreditOutstandingAmount |
As of December 31, 2024, we had no borrowings outstanding under our revolving credit facility. We had $ 2.1 million in letters of credit outstanding under the Prior Credit Agreement at December 31, 2024 and, as a result, had available borrowing capacity of approximately $ 613 million at that date. | text | 613 | monetaryItemType | text: <entity> 613 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we had no borrowings outstanding under our revolving credit facility. We had $ 2.1 million in letters of credit outstanding under the Prior Credit Agreement at December 31, 2024 and, as a result, had available borrowing capacity of approximately $ 613 million at that date. </context> | us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity |
— On March 16, 2015, we entered into a Reimbursement Agreement (as amended from time to time, the “Reimbursement Agreement”) with The Bank of Nova Scotia (“Scotiabank”), pursuant to which we may from time to time request that Scotiabank issue an unspecified amount of letters of credit. As of December 31, 2024, we had $ 38.8 million in letters of credit outstanding under the Reimbursement Agreement. | text | 38.8 | monetaryItemType | text: <entity> 38.8 </entity> <entity type> monetaryItemType </entity type> <context> — On March 16, 2015, we entered into a Reimbursement Agreement (as amended from time to time, the “Reimbursement Agreement”) with The Bank of Nova Scotia (“Scotiabank”), pursuant to which we may from time to time request that Scotiabank issue an unspecified amount of letters of credit. As of December 31, 2024, we had $ 38.8 million in letters of credit outstanding under the Reimbursement Agreement. </context> | us-gaap:LettersOfCreditOutstandingAmount |
Under the terms of the Reimbursement Agreement, we will reimburse Scotiabank on demand for any amounts that Scotiabank has disbursed under any of our letters of credit issued thereunder. Fees, charges and other reasonable expenses for the issuance of letters of credit are payable by us at the time of issuance at such rates and amounts as are in accordance with Scotiabank’s prevailing practice. We are obligated to pay to Scotiabank interest on all amounts not paid by us on the date of demand or when otherwise due at the Prime rate plus 2.00 % per annum, calculated daily and payable monthly, in arrears, on the basis of a calendar year for the actual number of days elapsed, with interest on overdue interest at the same rate as on the reimbursement amounts. A letter of credit fee is payable by us equal to 1.50 % times the amount of outstanding letters of credit. | text | 2.00 | percentItemType | text: <entity> 2.00 </entity> <entity type> percentItemType </entity type> <context> Under the terms of the Reimbursement Agreement, we will reimburse Scotiabank on demand for any amounts that Scotiabank has disbursed under any of our letters of credit issued thereunder. Fees, charges and other reasonable expenses for the issuance of letters of credit are payable by us at the time of issuance at such rates and amounts as are in accordance with Scotiabank’s prevailing practice. We are obligated to pay to Scotiabank interest on all amounts not paid by us on the date of demand or when otherwise due at the Prime rate plus 2.00 % per annum, calculated daily and payable monthly, in arrears, on the basis of a calendar year for the actual number of days elapsed, with interest on overdue interest at the same rate as on the reimbursement amounts. A letter of credit fee is payable by us equal to 1.50 % times the amount of outstanding letters of credit. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Under the terms of the Reimbursement Agreement, we will reimburse Scotiabank on demand for any amounts that Scotiabank has disbursed under any of our letters of credit issued thereunder. Fees, charges and other reasonable expenses for the issuance of letters of credit are payable by us at the time of issuance at such rates and amounts as are in accordance with Scotiabank’s prevailing practice. We are obligated to pay to Scotiabank interest on all amounts not paid by us on the date of demand or when otherwise due at the Prime rate plus 2.00 % per annum, calculated daily and payable monthly, in arrears, on the basis of a calendar year for the actual number of days elapsed, with interest on overdue interest at the same rate as on the reimbursement amounts. A letter of credit fee is payable by us equal to 1.50 % times the amount of outstanding letters of credit. | text | 1.50 | percentItemType | text: <entity> 1.50 </entity> <entity type> percentItemType </entity type> <context> Under the terms of the Reimbursement Agreement, we will reimburse Scotiabank on demand for any amounts that Scotiabank has disbursed under any of our letters of credit issued thereunder. Fees, charges and other reasonable expenses for the issuance of letters of credit are payable by us at the time of issuance at such rates and amounts as are in accordance with Scotiabank’s prevailing practice. We are obligated to pay to Scotiabank interest on all amounts not paid by us on the date of demand or when otherwise due at the Prime rate plus 2.00 % per annum, calculated daily and payable monthly, in arrears, on the basis of a calendar year for the actual number of days elapsed, with interest on overdue interest at the same rate as on the reimbursement amounts. A letter of credit fee is payable by us equal to 1.50 % times the amount of outstanding letters of credit. </context> | us-gaap:LineOfCreditFacilityInterestRateDuringPeriod |
—On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. | text | 525 | monetaryItemType | text: <entity> 525 </entity> <entity type> monetaryItemType </entity type> <context> —On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. </context> | us-gaap:DebtInstrumentFaceAmount |
—On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. | text | 3.95 | percentItemType | text: <entity> 3.95 </entity> <entity type> percentItemType </entity type> <context> —On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
—On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. | text | 350 | monetaryItemType | text: <entity> 350 </entity> <entity type> monetaryItemType </entity type> <context> —On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. </context> | us-gaap:DebtInstrumentFaceAmount |
—On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. | text | 5.15 | percentItemType | text: <entity> 5.15 </entity> <entity type> percentItemType </entity type> <context> —On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
—On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> —On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. </context> | us-gaap:DebtInstrumentFaceAmount |
—On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. | text | 7.15 | percentItemType | text: <entity> 7.15 </entity> <entity type> percentItemType </entity type> <context> —On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
—On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. | text | 396 | monetaryItemType | text: <entity> 396 </entity> <entity type> monetaryItemType </entity type> <context> —On January 19, 2018, we completed an offering of $ 525 million in aggregate principal amount of 3.95 % Senior Notes due 2028 (the “2028 Notes”). On November 15, 2019, we completed an offering of $ 350 million in aggregate principal amount of 5.15 % Senior Notes due 2029 (the “2029 Notes”). On September 13, 2023, we completed an offering of $ 400 million in aggregate principal amount of 7.15 % Senior Notes due 2033 (the “2033 Notes”). The net proceeds before offering expenses from the offering of the 2033 Notes were approximately $ 396 million, which we used to repay amounts outstanding under our Prior Credit Agreement. </context> | us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt |
We pay interest on the 2028 Notes on February 1 and August 1 of each year. The 2028 Notes will mature on February 1, 2028 . The 2028 Notes bear interest at a rate of 3.95 % per annum. | text | 3.95 | percentItemType | text: <entity> 3.95 </entity> <entity type> percentItemType </entity type> <context> We pay interest on the 2028 Notes on February 1 and August 1 of each year. The 2028 Notes will mature on February 1, 2028 . The 2028 Notes bear interest at a rate of 3.95 % per annum. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
We pay interest on the 2029 Notes on May 15 and November 15 of each year. The 2029 Notes will mature on November 15, 2029 . The 2029 Notes bear interest at a rate of 5.15 % per annum. | text | 5.15 | percentItemType | text: <entity> 5.15 </entity> <entity type> percentItemType </entity type> <context> We pay interest on the 2029 Notes on May 15 and November 15 of each year. The 2029 Notes will mature on November 15, 2029 . The 2029 Notes bear interest at a rate of 5.15 % per annum. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
We pay interest on the 2033 Notes on April 1 and October 1 of each year. The 2033 Notes will mature on October 1, 2033 . The 2033 Notes bear interest at a rate of 7.15 % per annum. | text | 7.15 | percentItemType | text: <entity> 7.15 </entity> <entity type> percentItemType </entity type> <context> We pay interest on the 2033 Notes on April 1 and October 1 of each year. The 2033 Notes will mature on October 1, 2033 . The 2033 Notes bear interest at a rate of 7.15 % per annum. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
As of December 31, 2024, we maintained letters of credit in the aggregate amount of $ 42.9 million primarily for the benefit of various insurance companies as collateral for retrospective premiums and retained losses that could become payable under the terms of the underlying insurance contracts and compliance with contractual obligations. These letters of credit expire annually at various times during the year and are typically renewed. As of December 31, 2024, no amounts had been drawn under the letters of credit. As of December 31, 2024, we had $ 35.0 million in surety bond exposure issued as financial assurance on an insurance agreement. | text | 42.9 | monetaryItemType | text: <entity> 42.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we maintained letters of credit in the aggregate amount of $ 42.9 million primarily for the benefit of various insurance companies as collateral for retrospective premiums and retained losses that could become payable under the terms of the underlying insurance contracts and compliance with contractual obligations. These letters of credit expire annually at various times during the year and are typically renewed. As of December 31, 2024, no amounts had been drawn under the letters of credit. As of December 31, 2024, we had $ 35.0 million in surety bond exposure issued as financial assurance on an insurance agreement. </context> | us-gaap:LettersOfCreditOutstandingAmount |
As of December 31, 2024, we maintained letters of credit in the aggregate amount of $ 42.9 million primarily for the benefit of various insurance companies as collateral for retrospective premiums and retained losses that could become payable under the terms of the underlying insurance contracts and compliance with contractual obligations. These letters of credit expire annually at various times during the year and are typically renewed. As of December 31, 2024, no amounts had been drawn under the letters of credit. As of December 31, 2024, we had $ 35.0 million in surety bond exposure issued as financial assurance on an insurance agreement. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we maintained letters of credit in the aggregate amount of $ 42.9 million primarily for the benefit of various insurance companies as collateral for retrospective premiums and retained losses that could become payable under the terms of the underlying insurance contracts and compliance with contractual obligations. These letters of credit expire annually at various times during the year and are typically renewed. As of December 31, 2024, no amounts had been drawn under the letters of credit. As of December 31, 2024, we had $ 35.0 million in surety bond exposure issued as financial assurance on an insurance agreement. </context> | us-gaap:LineOfCredit |
As of December 31, 2024, we maintained letters of credit in the aggregate amount of $ 42.9 million primarily for the benefit of various insurance companies as collateral for retrospective premiums and retained losses that could become payable under the terms of the underlying insurance contracts and compliance with contractual obligations. These letters of credit expire annually at various times during the year and are typically renewed. As of December 31, 2024, no amounts had been drawn under the letters of credit. As of December 31, 2024, we had $ 35.0 million in surety bond exposure issued as financial assurance on an insurance agreement. | text | 35.0 | monetaryItemType | text: <entity> 35.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we maintained letters of credit in the aggregate amount of $ 42.9 million primarily for the benefit of various insurance companies as collateral for retrospective premiums and retained losses that could become payable under the terms of the underlying insurance contracts and compliance with contractual obligations. These letters of credit expire annually at various times during the year and are typically renewed. As of December 31, 2024, no amounts had been drawn under the letters of credit. As of December 31, 2024, we had $ 35.0 million in surety bond exposure issued as financial assurance on an insurance agreement. </context> | us-gaap:OffBalanceSheetCreditLossLiability |
As of December 31, 2024, we had commitments to purchase major equipment totaling approximately $ 65.9 million. | text | 65.9 | monetaryItemType | text: <entity> 65.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we had commitments to purchase major equipment totaling approximately $ 65.9 million. </context> | us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted |
Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. | text | 103 | monetaryItemType | text: <entity> 103 </entity> <entity type> monetaryItemType </entity type> <context> Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. </context> | us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases |
Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. | text | 135 | monetaryItemType | text: <entity> 135 </entity> <entity type> monetaryItemType </entity type> <context> Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. </context> | us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases |
Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. | text | 93.0 | monetaryItemType | text: <entity> 93.0 </entity> <entity type> monetaryItemType </entity type> <context> Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. </context> | us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases |
Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. | text | 19.8 | monetaryItemType | text: <entity> 19.8 </entity> <entity type> monetaryItemType </entity type> <context> Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. </context> | us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount |
Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. | text | 17.4 | monetaryItemType | text: <entity> 17.4 </entity> <entity type> monetaryItemType </entity type> <context> Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. </context> | us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary |
Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. | text | 2.4 | monetaryItemType | text: <entity> 2.4 </entity> <entity type> monetaryItemType </entity type> <context> Our completion services segment has entered into agreements to purchase minimum quantities of proppants from certain vendors. We purchased $ 103 million, $ 135 million and $ 93.0 million of proppants under take-or-pay or similar agreements during the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, the remaining minimum obligation under these agreements was approximately $ 19.8 million, of which approximately, $ 17.4 million and $ 2.4 million relate to 2025 and 2026, respectively. </context> | us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary |
— On February 5, 2025, our Board of Directors approved a cash dividend on our common stock in the amount of $ 0.08 per share to be paid on March 17, 2025 to holders of record as of March 3, 2025. The amount and timing of all future dividend payments, if any, are subject to the discretion of the Board of Directors and will depend upon business conditions, results of operations, financial condition, terms of our debt agreements and other factors. Our Board of Directors may, without advance notice, reduce or suspend our dividend for any reason, including to improve our financial flexibility and position our company for long-term success. There can be no assurance that we will pay a dividend in the future. | text | 0.08 | perShareItemType | text: <entity> 0.08 </entity> <entity type> perShareItemType </entity type> <context> — On February 5, 2025, our Board of Directors approved a cash dividend on our common stock in the amount of $ 0.08 per share to be paid on March 17, 2025 to holders of record as of March 3, 2025. The amount and timing of all future dividend payments, if any, are subject to the discretion of the Board of Directors and will depend upon business conditions, results of operations, financial condition, terms of our debt agreements and other factors. Our Board of Directors may, without advance notice, reduce or suspend our dividend for any reason, including to improve our financial flexibility and position our company for long-term success. There can be no assurance that we will pay a dividend in the future. </context> | us-gaap:CommonStockDividendsPerShareDeclared |
— In September 2013, our Board of Directors approved a stock buyback program. In February 2024, our Board of Directors approved an increase of the authorization under the stock buyback program to allow for an aggregate of $ 1.0 billion of future share repurchases. All purchases executed to date have been through open market transactions. Purchases under the buyback program are made at management’s discretion, at prevailing prices, subject to market conditions and other factors. Purchases may be made at any time without prior notice. There is no expiration date associated with the buyback program. As of December 31, 2024, we had remaining authorization to purchase approximately $ 759 million of our outstanding common stock under the stock buyback program. Shares of stock purchased under the buyback program are held as treasury shares. | text | 759 | monetaryItemType | text: <entity> 759 </entity> <entity type> monetaryItemType </entity type> <context> — In September 2013, our Board of Directors approved a stock buyback program. In February 2024, our Board of Directors approved an increase of the authorization under the stock buyback program to allow for an aggregate of $ 1.0 billion of future share repurchases. All purchases executed to date have been through open market transactions. Purchases under the buyback program are made at management’s discretion, at prevailing prices, subject to market conditions and other factors. Purchases may be made at any time without prior notice. There is no expiration date associated with the buyback program. As of December 31, 2024, we had remaining authorization to purchase approximately $ 759 million of our outstanding common stock under the stock buyback program. Shares of stock purchased under the buyback program are held as treasury shares. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
The 2021 Plan was originally approved by our stockholders on June 3, 2021. Our Board of Directors and our stockholders have approved a series of amendments to the 2021 Plan (the “2021 Plan Amendments”) to increase the number of shares available for issuance under the 2021 Plan. Following the 2021 Plan Amendments, the aggregate number of shares of Common Stock authorized for grant under the 2021 Plan is approximately 39.1 million. | text | 39.1 | sharesItemType | text: <entity> 39.1 </entity> <entity type> sharesItemType </entity type> <context> The 2021 Plan was originally approved by our stockholders on June 3, 2021. Our Board of Directors and our stockholders have approved a series of amendments to the 2021 Plan (the “2021 Plan Amendments”) to increase the number of shares available for issuance under the 2021 Plan. Following the 2021 Plan Amendments, the aggregate number of shares of Common Stock authorized for grant under the 2021 Plan is approximately 39.1 million. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
— We converted NexTier’s cash-settled performance based units into our cash-settled restricted stock units in connection with the NexTier merger. These awards are accounted for as liability classified awards and remeasured at fair value at each reporting period. Compensation expense is recorded over the vesting period and is initially based on the fair value at the award conversion date. Compensation expense is subsequently remeasured at each reporting date during the vesting period based on the change in our stock price. Dividend cash equivalents are not paid on cash-settled units. As of December 31, 2024, $ 3.3 million is included in “Accrued liabilities” in our consolidated balance sheets for these awards. We recognized $ 0.6 million of compensation expense for these awards during the year ended December 31, 2024. | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> — We converted NexTier’s cash-settled performance based units into our cash-settled restricted stock units in connection with the NexTier merger. These awards are accounted for as liability classified awards and remeasured at fair value at each reporting period. Compensation expense is recorded over the vesting period and is initially based on the fair value at the award conversion date. Compensation expense is subsequently remeasured at each reporting date during the vesting period based on the change in our stock price. Dividend cash equivalents are not paid on cash-settled units. As of December 31, 2024, $ 3.3 million is included in “Accrued liabilities” in our consolidated balance sheets for these awards. We recognized $ 0.6 million of compensation expense for these awards during the year ended December 31, 2024. </context> | us-gaap:AccruedLiabilitiesCurrentAndNoncurrent |
— We converted NexTier’s cash-settled performance based units into our cash-settled restricted stock units in connection with the NexTier merger. These awards are accounted for as liability classified awards and remeasured at fair value at each reporting period. Compensation expense is recorded over the vesting period and is initially based on the fair value at the award conversion date. Compensation expense is subsequently remeasured at each reporting date during the vesting period based on the change in our stock price. Dividend cash equivalents are not paid on cash-settled units. As of December 31, 2024, $ 3.3 million is included in “Accrued liabilities” in our consolidated balance sheets for these awards. We recognized $ 0.6 million of compensation expense for these awards during the year ended December 31, 2024. | text | 0.6 | monetaryItemType | text: <entity> 0.6 </entity> <entity type> monetaryItemType </entity type> <context> — We converted NexTier’s cash-settled performance based units into our cash-settled restricted stock units in connection with the NexTier merger. These awards are accounted for as liability classified awards and remeasured at fair value at each reporting period. Compensation expense is recorded over the vesting period and is initially based on the fair value at the award conversion date. Compensation expense is subsequently remeasured at each reporting date during the vesting period based on the change in our stock price. Dividend cash equivalents are not paid on cash-settled units. As of December 31, 2024, $ 3.3 million is included in “Accrued liabilities” in our consolidated balance sheets for these awards. We recognized $ 0.6 million of compensation expense for these awards during the year ended December 31, 2024. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost |
As of December 31, 2024, we had unrecognized compensation cost of $ 12.8 million related to our unvested Performance Units. The weighted-average remaining vesting period for these unvested Performance Units was 1.04 years as of December 31, 2024. | text | 12.8 | monetaryItemType | text: <entity> 12.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we had unrecognized compensation cost of $ 12.8 million related to our unvested Performance Units. The weighted-average remaining vesting period for these unvested Performance Units was 1.04 years as of December 31, 2024. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
— In May 2020, the Compensation Committee approved a grant of long-term performance-based phantom units to our Chief Executive Officer and President, William A. Hendricks, Jr. (the “Phantom Units”). The Phantom Units were granted outside of the 2014 Plan. Pursuant to this phantom unit grant, Mr. Hendricks could earn from 0 % to 200 % of a target award of 298,500 phantom units based on our achievement of the same performance conditions over the same performance period that applied to the Performance Units granted in April 2020. The Phantom Units settled in May 2023, with a cash payment of $ 7.4 million. | text | 0 | percentItemType | text: <entity> 0 </entity> <entity type> percentItemType </entity type> <context> — In May 2020, the Compensation Committee approved a grant of long-term performance-based phantom units to our Chief Executive Officer and President, William A. Hendricks, Jr. (the “Phantom Units”). The Phantom Units were granted outside of the 2014 Plan. Pursuant to this phantom unit grant, Mr. Hendricks could earn from 0 % to 200 % of a target award of 298,500 phantom units based on our achievement of the same performance conditions over the same performance period that applied to the Performance Units granted in April 2020. The Phantom Units settled in May 2023, with a cash payment of $ 7.4 million. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
— In May 2020, the Compensation Committee approved a grant of long-term performance-based phantom units to our Chief Executive Officer and President, William A. Hendricks, Jr. (the “Phantom Units”). The Phantom Units were granted outside of the 2014 Plan. Pursuant to this phantom unit grant, Mr. Hendricks could earn from 0 % to 200 % of a target award of 298,500 phantom units based on our achievement of the same performance conditions over the same performance period that applied to the Performance Units granted in April 2020. The Phantom Units settled in May 2023, with a cash payment of $ 7.4 million. | text | 200 | percentItemType | text: <entity> 200 </entity> <entity type> percentItemType </entity type> <context> — In May 2020, the Compensation Committee approved a grant of long-term performance-based phantom units to our Chief Executive Officer and President, William A. Hendricks, Jr. (the “Phantom Units”). The Phantom Units were granted outside of the 2014 Plan. Pursuant to this phantom unit grant, Mr. Hendricks could earn from 0 % to 200 % of a target award of 298,500 phantom units based on our achievement of the same performance conditions over the same performance period that applied to the Performance Units granted in April 2020. The Phantom Units settled in May 2023, with a cash payment of $ 7.4 million. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
— In May 2020, the Compensation Committee approved a grant of long-term performance-based phantom units to our Chief Executive Officer and President, William A. Hendricks, Jr. (the “Phantom Units”). The Phantom Units were granted outside of the 2014 Plan. Pursuant to this phantom unit grant, Mr. Hendricks could earn from 0 % to 200 % of a target award of 298,500 phantom units based on our achievement of the same performance conditions over the same performance period that applied to the Performance Units granted in April 2020. The Phantom Units settled in May 2023, with a cash payment of $ 7.4 million. | text | 298500 | sharesItemType | text: <entity> 298500 </entity> <entity type> sharesItemType </entity type> <context> — In May 2020, the Compensation Committee approved a grant of long-term performance-based phantom units to our Chief Executive Officer and President, William A. Hendricks, Jr. (the “Phantom Units”). The Phantom Units were granted outside of the 2014 Plan. Pursuant to this phantom unit grant, Mr. Hendricks could earn from 0 % to 200 % of a target award of 298,500 phantom units based on our achievement of the same performance conditions over the same performance period that applied to the Performance Units granted in April 2020. The Phantom Units settled in May 2023, with a cash payment of $ 7.4 million. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
— In May 2020, the Compensation Committee approved a grant of long-term performance-based phantom units to our Chief Executive Officer and President, William A. Hendricks, Jr. (the “Phantom Units”). The Phantom Units were granted outside of the 2014 Plan. Pursuant to this phantom unit grant, Mr. Hendricks could earn from 0 % to 200 % of a target award of 298,500 phantom units based on our achievement of the same performance conditions over the same performance period that applied to the Performance Units granted in April 2020. The Phantom Units settled in May 2023, with a cash payment of $ 7.4 million. | text | 7.4 | monetaryItemType | text: <entity> 7.4 </entity> <entity type> monetaryItemType </entity type> <context> — In May 2020, the Compensation Committee approved a grant of long-term performance-based phantom units to our Chief Executive Officer and President, William A. Hendricks, Jr. (the “Phantom Units”). The Phantom Units were granted outside of the 2014 Plan. Pursuant to this phantom unit grant, Mr. Hendricks could earn from 0 % to 200 % of a target award of 298,500 phantom units based on our achievement of the same performance conditions over the same performance period that applied to the Performance Units granted in April 2020. The Phantom Units settled in May 2023, with a cash payment of $ 7.4 million. </context> | us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount |
During the third quarter of 2023, we acquired $ 7.5 million and $ 19.1 million of operating leases for operating locations, corporate offices, certain operating equipment and light duty vehicles primarily related to the Ulterra acquisition and NexTier merger, respectively. | text | 7.5 | monetaryItemType | text: <entity> 7.5 </entity> <entity type> monetaryItemType </entity type> <context> During the third quarter of 2023, we acquired $ 7.5 million and $ 19.1 million of operating leases for operating locations, corporate offices, certain operating equipment and light duty vehicles primarily related to the Ulterra acquisition and NexTier merger, respectively. </context> | us-gaap:OperatingLeaseLiability |
During the third quarter of 2023, we acquired $ 7.5 million and $ 19.1 million of operating leases for operating locations, corporate offices, certain operating equipment and light duty vehicles primarily related to the Ulterra acquisition and NexTier merger, respectively. | text | 19.1 | monetaryItemType | text: <entity> 19.1 </entity> <entity type> monetaryItemType </entity type> <context> During the third quarter of 2023, we acquired $ 7.5 million and $ 19.1 million of operating leases for operating locations, corporate offices, certain operating equipment and light duty vehicles primarily related to the Ulterra acquisition and NexTier merger, respectively. </context> | us-gaap:OperatingLeaseLiability |
We also acquired $ 5.2 million and $ 50.7 million of finance leases for light duty vehicles and certain operating equipment related to the Ulterra acquisition and NexTier merger, respectively. | text | 5.2 | monetaryItemType | text: <entity> 5.2 </entity> <entity type> monetaryItemType </entity type> <context> We also acquired $ 5.2 million and $ 50.7 million of finance leases for light duty vehicles and certain operating equipment related to the Ulterra acquisition and NexTier merger, respectively. </context> | us-gaap:FinanceLeaseLiability |
We also acquired $ 5.2 million and $ 50.7 million of finance leases for light duty vehicles and certain operating equipment related to the Ulterra acquisition and NexTier merger, respectively. | text | 50.7 | monetaryItemType | text: <entity> 50.7 </entity> <entity type> monetaryItemType </entity type> <context> We also acquired $ 5.2 million and $ 50.7 million of finance leases for light duty vehicles and certain operating equipment related to the Ulterra acquisition and NexTier merger, respectively. </context> | us-gaap:FinanceLeaseLiability |
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized, and when necessary, valuation allowances are provided. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We assess the realizability of our deferred tax assets quarterly and consider carryback availability, the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. During 2024, we increased the valuation allowance against our net deferred tax assets by $ 11.4 million, which primarily related to U.S. state and foreign activity. | text | 11.4 | monetaryItemType | text: <entity> 11.4 </entity> <entity type> monetaryItemType </entity type> <context> In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized, and when necessary, valuation allowances are provided. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We assess the realizability of our deferred tax assets quarterly and consider carryback availability, the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. During 2024, we increased the valuation allowance against our net deferred tax assets by $ 11.4 million, which primarily related to U.S. state and foreign activity. </context> | us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount |
For income tax purposes, we had approximately $ 1.5 billion of gross U.S. federal net operating losses, approximately $ 58.7 million of gross Canadian net operating losses and approximately $ 910 million of post-apportionment U.S. state net operating losses as of December 31, 2024, before valuation allowances. The majority of the U.S. federal net operating losses are generated after 2017 and can be carried forward indefinitely. Canadian net operating losses will expire in varying amounts, if unused, between 2036 and 2044 . U.S. state net operating losses will expire in varying amounts, if unused, between 2025 and 2044 . | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> For income tax purposes, we had approximately $ 1.5 billion of gross U.S. federal net operating losses, approximately $ 58.7 million of gross Canadian net operating losses and approximately $ 910 million of post-apportionment U.S. state net operating losses as of December 31, 2024, before valuation allowances. The majority of the U.S. federal net operating losses are generated after 2017 and can be carried forward indefinitely. Canadian net operating losses will expire in varying amounts, if unused, between 2036 and 2044 . U.S. state net operating losses will expire in varying amounts, if unused, between 2025 and 2044 . </context> | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic |
For income tax purposes, we had approximately $ 1.5 billion of gross U.S. federal net operating losses, approximately $ 58.7 million of gross Canadian net operating losses and approximately $ 910 million of post-apportionment U.S. state net operating losses as of December 31, 2024, before valuation allowances. The majority of the U.S. federal net operating losses are generated after 2017 and can be carried forward indefinitely. Canadian net operating losses will expire in varying amounts, if unused, between 2036 and 2044 . U.S. state net operating losses will expire in varying amounts, if unused, between 2025 and 2044 . | text | 58.7 | monetaryItemType | text: <entity> 58.7 </entity> <entity type> monetaryItemType </entity type> <context> For income tax purposes, we had approximately $ 1.5 billion of gross U.S. federal net operating losses, approximately $ 58.7 million of gross Canadian net operating losses and approximately $ 910 million of post-apportionment U.S. state net operating losses as of December 31, 2024, before valuation allowances. The majority of the U.S. federal net operating losses are generated after 2017 and can be carried forward indefinitely. Canadian net operating losses will expire in varying amounts, if unused, between 2036 and 2044 . U.S. state net operating losses will expire in varying amounts, if unused, between 2025 and 2044 . </context> | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign |
For income tax purposes, we had approximately $ 1.5 billion of gross U.S. federal net operating losses, approximately $ 58.7 million of gross Canadian net operating losses and approximately $ 910 million of post-apportionment U.S. state net operating losses as of December 31, 2024, before valuation allowances. The majority of the U.S. federal net operating losses are generated after 2017 and can be carried forward indefinitely. Canadian net operating losses will expire in varying amounts, if unused, between 2036 and 2044 . U.S. state net operating losses will expire in varying amounts, if unused, between 2025 and 2044 . | text | 910 | monetaryItemType | text: <entity> 910 </entity> <entity type> monetaryItemType </entity type> <context> For income tax purposes, we had approximately $ 1.5 billion of gross U.S. federal net operating losses, approximately $ 58.7 million of gross Canadian net operating losses and approximately $ 910 million of post-apportionment U.S. state net operating losses as of December 31, 2024, before valuation allowances. The majority of the U.S. federal net operating losses are generated after 2017 and can be carried forward indefinitely. Canadian net operating losses will expire in varying amounts, if unused, between 2036 and 2044 . U.S. state net operating losses will expire in varying amounts, if unused, between 2025 and 2044 . </context> | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal |
We maintain a 401(k) plan for all eligible employees. Our operating results include expenses of approximately $ 34.6 million | text | 34.6 | monetaryItemType | text: <entity> 34.6 </entity> <entity type> monetaryItemType </entity type> <context> We maintain a 401(k) plan for all eligible employees. Our operating results include expenses of approximately $ 34.6 million </context> | us-gaap:DefinedContributionPlanCostRecognized |
CODM manages and allocates resources to our business as a result of the Ulterra acquisition and NexTier merger. Our business is organized based on the services and products we provided in three segments: (i) drilling services, (ii) completion services, and (iii) drilling products. The CODM evaluates segment performance based primarily on segment operating income (loss). | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> CODM manages and allocates resources to our business as a result of the Ulterra acquisition and NexTier merger. Our business is organized based on the services and products we provided in three segments: (i) drilling services, (ii) completion services, and (iii) drilling products. The CODM evaluates segment performance based primarily on segment operating income (loss). </context> | us-gaap:NumberOfReportableSegments |
— During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. | text | 605 | monetaryItemType | text: <entity> 605 </entity> <entity type> monetaryItemType </entity type> <context> — During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
— During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. | text | 11 | percentItemType | text: <entity> 11 </entity> <entity type> percentItemType </entity type> <context> — During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. </context> | us-gaap:ConcentrationRiskPercentage1 |
— During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. | text | 588 | monetaryItemType | text: <entity> 588 </entity> <entity type> monetaryItemType </entity type> <context> — During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
— During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. | text | 14 | percentItemType | text: <entity> 14 </entity> <entity type> percentItemType </entity type> <context> — During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. </context> | us-gaap:ConcentrationRiskPercentage1 |
— During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. | text | 476 | monetaryItemType | text: <entity> 476 </entity> <entity type> monetaryItemType </entity type> <context> — During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
— During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. | text | 18 | percentItemType | text: <entity> 18 </entity> <entity type> percentItemType </entity type> <context> — During 2024, one customer accounted for approximately $ 605 million or 11 % of our consolidated operating revenues. These revenues were earned in the drilling services, completion services, and drilling products businesses. During 2023, one customer accounted for approximately $ 588 million or 14 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. During 2022, one customer accounted for approximately $ 476 million or 18 % of our consolidated operating revenues. These revenues were earned in both drilling services and completion services businesses. </context> | us-gaap:ConcentrationRiskPercentage1 |
On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO®, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $ 1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $ 200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application approval from the FDA with an approved label that permits vorasidenib’s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase, or IDH, 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), or the Vorasidenib Milestone Payment, as well as a royalty of 5 % of U.S. net sales of TIBSOVO® from the close of the transaction through loss of exclusivity, and a royalty of 15 % of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity, or the Vorasidenib Royalty Rights. The Vorasidenib Milestone Payment, Vorasidenib Royalty Rights and royalty payments related to TIBSOVO® are referred to as contingent payments and recognized as income when realizable. Servier also acquired our co-commercialization rights for Bristol Myers Squibb’s IDHIFA® and the right to receive a $ 25.0 million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier has agreed to conduct certain clinical development activities within the IDHIFA® development program. | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO®, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $ 1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $ 200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application approval from the FDA with an approved label that permits vorasidenib’s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase, or IDH, 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), or the Vorasidenib Milestone Payment, as well as a royalty of 5 % of U.S. net sales of TIBSOVO® from the close of the transaction through loss of exclusivity, and a royalty of 15 % of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity, or the Vorasidenib Royalty Rights. The Vorasidenib Milestone Payment, Vorasidenib Royalty Rights and royalty payments related to TIBSOVO® are referred to as contingent payments and recognized as income when realizable. Servier also acquired our co-commercialization rights for Bristol Myers Squibb’s IDHIFA® and the right to receive a $ 25.0 million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier has agreed to conduct certain clinical development activities within the IDHIFA® development program. </context> | us-gaap:ProceedsFromDivestitureOfBusinesses |
On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO®, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $ 1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $ 200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application approval from the FDA with an approved label that permits vorasidenib’s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase, or IDH, 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), or the Vorasidenib Milestone Payment, as well as a royalty of 5 % of U.S. net sales of TIBSOVO® from the close of the transaction through loss of exclusivity, and a royalty of 15 % of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity, or the Vorasidenib Royalty Rights. The Vorasidenib Milestone Payment, Vorasidenib Royalty Rights and royalty payments related to TIBSOVO® are referred to as contingent payments and recognized as income when realizable. Servier also acquired our co-commercialization rights for Bristol Myers Squibb’s IDHIFA® and the right to receive a $ 25.0 million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier has agreed to conduct certain clinical development activities within the IDHIFA® development program. | text | 200.0 | monetaryItemType | text: <entity> 200.0 </entity> <entity type> monetaryItemType </entity type> <context> On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO®, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $ 1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $ 200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application approval from the FDA with an approved label that permits vorasidenib’s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase, or IDH, 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), or the Vorasidenib Milestone Payment, as well as a royalty of 5 % of U.S. net sales of TIBSOVO® from the close of the transaction through loss of exclusivity, and a royalty of 15 % of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity, or the Vorasidenib Royalty Rights. The Vorasidenib Milestone Payment, Vorasidenib Royalty Rights and royalty payments related to TIBSOVO® are referred to as contingent payments and recognized as income when realizable. Servier also acquired our co-commercialization rights for Bristol Myers Squibb’s IDHIFA® and the right to receive a $ 25.0 million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier has agreed to conduct certain clinical development activities within the IDHIFA® development program. </context> | us-gaap:GainContingencyUnrecordedAmount |
In August 2024, the FDA approved vorasidenib for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. In September 2024, we received the Vorasidenib Milestone Payment from Servier and recognized income of $ 200.0 million within the milestone payment from gain on sale of oncology business line item in our consolidated statements of operations for the year ended December 31, 2024. In May 2024, we entered into a purchase and sale agreement to sell the Vorasidenib Royalty Rights to Royalty Pharma Investments 2019 ICAV, or Royalty Pharma, for $ 905.0 million in cash, or the Upfront Payment. The sale was contingent upon FDA approval of vorasidenib and other customary closing conditions. | text | 200.0 | monetaryItemType | text: <entity> 200.0 </entity> <entity type> monetaryItemType </entity type> <context> In August 2024, the FDA approved vorasidenib for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. In September 2024, we received the Vorasidenib Milestone Payment from Servier and recognized income of $ 200.0 million within the milestone payment from gain on sale of oncology business line item in our consolidated statements of operations for the year ended December 31, 2024. In May 2024, we entered into a purchase and sale agreement to sell the Vorasidenib Royalty Rights to Royalty Pharma Investments 2019 ICAV, or Royalty Pharma, for $ 905.0 million in cash, or the Upfront Payment. The sale was contingent upon FDA approval of vorasidenib and other customary closing conditions. </context> | us-gaap:RoyaltyIncomeNonoperating |
As of December 31, 2024, we had cash, cash equivalents and marketable securities of $ 1.5 billion. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities to be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. If we are unable to raise additional funds through equity or debt financings, we may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we had cash, cash equivalents and marketable securities of $ 1.5 billion. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities to be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. If we are unable to raise additional funds through equity or debt financings, we may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </context> | us-gaap:CashCashEquivalentsAndShortTermInvestments |
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or CODM, or decision-making group in making decisions on how to allocate resources and assess performance. Our CODM is our chief executive officer, or CEO. Our CEO views our operations and manages our business as one operating segment, which derives its revenues from the development and commercialization of therapies for patients with rare diseases. | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or CODM, or decision-making group in making decisions on how to allocate resources and assess performance. Our CODM is our chief executive officer, or CEO. Our CEO views our operations and manages our business as one operating segment, which derives its revenues from the development and commercialization of therapies for patients with rare diseases. </context> | us-gaap:NumberOfOperatingSegments |
There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level 3 at any point during the year ended December 31, 2024. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level 3 at any point during the year ended December 31, 2024. </context> | us-gaap:FairValueNetAssetLiability |
At December 31, 2024 and 2023, we held 213 and 151 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2024 and 2023 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2024 and 2023 was $ 768.1 million and $ 513.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2024 and 2023. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2024 and 2023. | text | 213 | integerItemType | text: <entity> 213 </entity> <entity type> integerItemType </entity type> <context> At December 31, 2024 and 2023, we held 213 and 151 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2024 and 2023 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2024 and 2023 was $ 768.1 million and $ 513.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2024 and 2023. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2024 and 2023. </context> | us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions |
At December 31, 2024 and 2023, we held 213 and 151 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2024 and 2023 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2024 and 2023 was $ 768.1 million and $ 513.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2024 and 2023. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2024 and 2023. | text | 151 | integerItemType | text: <entity> 151 </entity> <entity type> integerItemType </entity type> <context> At December 31, 2024 and 2023, we held 213 and 151 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2024 and 2023 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2024 and 2023 was $ 768.1 million and $ 513.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2024 and 2023. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2024 and 2023. </context> | us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions |
At December 31, 2024 and 2023, we held 213 and 151 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2024 and 2023 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2024 and 2023 was $ 768.1 million and $ 513.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2024 and 2023. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2024 and 2023. | text | 768.1 | monetaryItemType | text: <entity> 768.1 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, we held 213 and 151 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2024 and 2023 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2024 and 2023 was $ 768.1 million and $ 513.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2024 and 2023. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2024 and 2023. </context> | us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition |
At December 31, 2024 and 2023, we held 213 and 151 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2024 and 2023 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2024 and 2023 was $ 768.1 million and $ 513.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2024 and 2023. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2024 and 2023. | text | 513.5 | monetaryItemType | text: <entity> 513.5 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024 and 2023, we held 213 and 151 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2024 and 2023 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2024 and 2023 was $ 768.1 million and $ 513.5 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2024 and 2023. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2024 and 2023. </context> | us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition |
In arriving at the operating lease liabilities as of December 31, 2024, we applied the weighted-average incremental borrowing rate of 5.7 % from inception over a weighted-average remaining lease term of 3.2 years. In arriving at the operating lease liabilities as of December 31, 2023, we applied the weighted-average incremental borrowing rate of 5.7 % over a weighted-average remaining lease term of 4.2 years. | text | 5.7 | percentItemType | text: <entity> 5.7 </entity> <entity type> percentItemType </entity type> <context> In arriving at the operating lease liabilities as of December 31, 2024, we applied the weighted-average incremental borrowing rate of 5.7 % from inception over a weighted-average remaining lease term of 3.2 years. In arriving at the operating lease liabilities as of December 31, 2023, we applied the weighted-average incremental borrowing rate of 5.7 % over a weighted-average remaining lease term of 4.2 years. </context> | us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent |
We provided our landlord a security deposit of $ 2.9 million as security for our leases, which is included within other non-current assets on our consolidated balance sheet. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> We provided our landlord a security deposit of $ 2.9 million as security for our leases, which is included within other non-current assets on our consolidated balance sheet. </context> | us-gaap:LettersOfCreditOutstandingAmount |
We recorded operating sublease income of $ 6.4 million and $ 6.1 million for the years ended December 31, 2024 and December 31, 2023, respectively, in other income, net in the consolidated statements of operations. We hold security deposits from our sublessees of approximately $ 0.9 million which is recorded within other non-current assets on our consolidated balance sheet. | text | 6.4 | monetaryItemType | text: <entity> 6.4 </entity> <entity type> monetaryItemType </entity type> <context> We recorded operating sublease income of $ 6.4 million and $ 6.1 million for the years ended December 31, 2024 and December 31, 2023, respectively, in other income, net in the consolidated statements of operations. We hold security deposits from our sublessees of approximately $ 0.9 million which is recorded within other non-current assets on our consolidated balance sheet. </context> | us-gaap:SubleaseIncome |
We recorded operating sublease income of $ 6.4 million and $ 6.1 million for the years ended December 31, 2024 and December 31, 2023, respectively, in other income, net in the consolidated statements of operations. We hold security deposits from our sublessees of approximately $ 0.9 million which is recorded within other non-current assets on our consolidated balance sheet. | text | 6.1 | monetaryItemType | text: <entity> 6.1 </entity> <entity type> monetaryItemType </entity type> <context> We recorded operating sublease income of $ 6.4 million and $ 6.1 million for the years ended December 31, 2024 and December 31, 2023, respectively, in other income, net in the consolidated statements of operations. We hold security deposits from our sublessees of approximately $ 0.9 million which is recorded within other non-current assets on our consolidated balance sheet. </context> | us-gaap:SubleaseIncome |
We recorded operating sublease income of $ 6.4 million and $ 6.1 million for the years ended December 31, 2024 and December 31, 2023, respectively, in other income, net in the consolidated statements of operations. We hold security deposits from our sublessees of approximately $ 0.9 million which is recorded within other non-current assets on our consolidated balance sheet. | text | 0.9 | monetaryItemType | text: <entity> 0.9 </entity> <entity type> monetaryItemType </entity type> <context> We recorded operating sublease income of $ 6.4 million and $ 6.1 million for the years ended December 31, 2024 and December 31, 2023, respectively, in other income, net in the consolidated statements of operations. We hold security deposits from our sublessees of approximately $ 0.9 million which is recorded within other non-current assets on our consolidated balance sheet. </context> | us-gaap:SecurityDepositLiability |
One Customer accounted for 95 %, 96 % and 97 % of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively, and 92 % and 97 % of accounts receivable from product sales for the years ended December 31, 2024 and 2023, respectively. | text | 95 | percentItemType | text: <entity> 95 </entity> <entity type> percentItemType </entity type> <context> One Customer accounted for 95 %, 96 % and 97 % of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively, and 92 % and 97 % of accounts receivable from product sales for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:ConcentrationRiskPercentage1 |
One Customer accounted for 95 %, 96 % and 97 % of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively, and 92 % and 97 % of accounts receivable from product sales for the years ended December 31, 2024 and 2023, respectively. | text | 96 | percentItemType | text: <entity> 96 </entity> <entity type> percentItemType </entity type> <context> One Customer accounted for 95 %, 96 % and 97 % of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively, and 92 % and 97 % of accounts receivable from product sales for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:ConcentrationRiskPercentage1 |
One Customer accounted for 95 %, 96 % and 97 % of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively, and 92 % and 97 % of accounts receivable from product sales for the years ended December 31, 2024 and 2023, respectively. | text | 97 | percentItemType | text: <entity> 97 </entity> <entity type> percentItemType </entity type> <context> One Customer accounted for 95 %, 96 % and 97 % of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively, and 92 % and 97 % of accounts receivable from product sales for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:ConcentrationRiskPercentage1 |
One Customer accounted for 95 %, 96 % and 97 % of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively, and 92 % and 97 % of accounts receivable from product sales for the years ended December 31, 2024 and 2023, respectively. | text | 92 | percentItemType | text: <entity> 92 </entity> <entity type> percentItemType </entity type> <context> One Customer accounted for 95 %, 96 % and 97 % of our consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively, and 92 % and 97 % of accounts receivable from product sales for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:ConcentrationRiskPercentage1 |
As of December 31, 2024, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 10,896,149 , and we had 2,868,747 shares available for future issuance under the 2023 Plan. | text | 10896149 | sharesItemType | text: <entity> 10896149 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2024, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 10,896,149 , and we had 2,868,747 shares available for future issuance under the 2023 Plan. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
As of December 31, 2024, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 10,896,149 , and we had 2,868,747 shares available for future issuance under the 2023 Plan. | text | 2868747 | sharesItemType | text: <entity> 2868747 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2024, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 10,896,149 , and we had 2,868,747 shares available for future issuance under the 2023 Plan. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. | text | 18.92 | perShareItemType | text: <entity> 18.92 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. | text | 14.32 | perShareItemType | text: <entity> 14.32 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. | text | 15.64 | perShareItemType | text: <entity> 15.64 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 18.92 , $ 14.32 and $ 15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $ 3.3 million, $ 2.9 million and $ 0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
At December 31, 2024, the total unrecognized compensation expense related to unvested stock option awards was $ 29.1 million, which we expect to recognize over a weighted-average period of approximately 2.37 years. | text | 29.1 | monetaryItemType | text: <entity> 29.1 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, the total unrecognized compensation expense related to unvested stock option awards was $ 29.1 million, which we expect to recognize over a weighted-average period of approximately 2.37 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions |
As of December 31, 2024, there was approximately $ 33.6 million of total unrecognized compensation expense related to RSUs, which we expect to be recognized over a weighted-average period of 1.87 years. | text | 33.6 | monetaryItemType | text: <entity> 33.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, there was approximately $ 33.6 million of total unrecognized compensation expense related to RSUs, which we expect to be recognized over a weighted-average period of 1.87 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions |
Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management’s best estimates. As of December 31, 2024, there was no unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement that we expect to recognize. There was $ 11.0 million of total unrecognized compensation expense related to PSUs | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management’s best estimates. As of December 31, 2024, there was no unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement that we expect to recognize. There was $ 11.0 million of total unrecognized compensation expense related to PSUs </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions |
As of December 31, 2024, there was no remaining unrecognized compensation expense related to MSUs. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, there was no remaining unrecognized compensation expense related to MSUs. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions |
In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 ESPP, which was further amended and restated by our Board of Directors in December 2024. We issued 102,805 shares and 112,832 shares during the years ended December 31, 2024 and 2023, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2024, we had 1,583,234 shares available for future issuance under the 2013 ESPP. | text | 102805 | sharesItemType | text: <entity> 102805 </entity> <entity type> sharesItemType </entity type> <context> In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 ESPP, which was further amended and restated by our Board of Directors in December 2024. We issued 102,805 shares and 112,832 shares during the years ended December 31, 2024 and 2023, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2024, we had 1,583,234 shares available for future issuance under the 2013 ESPP. </context> | us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans |
In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 ESPP, which was further amended and restated by our Board of Directors in December 2024. We issued 102,805 shares and 112,832 shares during the years ended December 31, 2024 and 2023, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2024, we had 1,583,234 shares available for future issuance under the 2013 ESPP. | text | 112832 | sharesItemType | text: <entity> 112832 </entity> <entity type> sharesItemType </entity type> <context> In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 ESPP, which was further amended and restated by our Board of Directors in December 2024. We issued 102,805 shares and 112,832 shares during the years ended December 31, 2024 and 2023, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2024, we had 1,583,234 shares available for future issuance under the 2013 ESPP. </context> | us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans |
In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 ESPP, which was further amended and restated by our Board of Directors in December 2024. We issued 102,805 shares and 112,832 shares during the years ended December 31, 2024 and 2023, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2024, we had 1,583,234 shares available for future issuance under the 2013 ESPP. | text | 2363636 | sharesItemType | text: <entity> 2363636 </entity> <entity type> sharesItemType </entity type> <context> In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 ESPP, which was further amended and restated by our Board of Directors in December 2024. We issued 102,805 shares and 112,832 shares during the years ended December 31, 2024 and 2023, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2024, we had 1,583,234 shares available for future issuance under the 2013 ESPP. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee |
In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 ESPP, which was further amended and restated by our Board of Directors in December 2024. We issued 102,805 shares and 112,832 shares during the years ended December 31, 2024 and 2023, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2024, we had 1,583,234 shares available for future issuance under the 2013 ESPP. | text | 1583234 | sharesItemType | text: <entity> 1583234 </entity> <entity type> sharesItemType </entity type> <context> In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 ESPP, which was further amended and restated by our Board of Directors in December 2024. We issued 102,805 shares and 112,832 shares during the years ended December 31, 2024 and 2023, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2024, we had 1,583,234 shares available for future issuance under the 2013 ESPP. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
We have never paid, and do not anticipate paying, any cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the option-pricing model. | text | zero | percentItemType | text: <entity> zero </entity> <entity type> percentItemType </entity type> <context> We have never paid, and do not anticipate paying, any cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the option-pricing model. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
The Tax Cuts and Jobs Act, or TCJA, requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. We capitalized research and experimental costs of $ 244.9 million and $ 232.7 million for the years ended December 31, 2024 and December 31, 2023, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S. | text | 244.9 | monetaryItemType | text: <entity> 244.9 </entity> <entity type> monetaryItemType </entity type> <context> The Tax Cuts and Jobs Act, or TCJA, requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. We capitalized research and experimental costs of $ 244.9 million and $ 232.7 million for the years ended December 31, 2024 and December 31, 2023, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S. </context> | us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts |
The Tax Cuts and Jobs Act, or TCJA, requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. We capitalized research and experimental costs of $ 244.9 million and $ 232.7 million for the years ended December 31, 2024 and December 31, 2023, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S. | text | 232.7 | monetaryItemType | text: <entity> 232.7 </entity> <entity type> monetaryItemType </entity type> <context> The Tax Cuts and Jobs Act, or TCJA, requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. We capitalized research and experimental costs of $ 244.9 million and $ 232.7 million for the years ended December 31, 2024 and December 31, 2023, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S. </context> | us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts |
As of December 31, 2024, we had net operating loss carryforwards, or NOLs, available to reduce state and foreign income taxes of approximately $ 320.0 million and $ 65.2 million, respectively. At December 31, 2024, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 23.2 million and $ 29.3 million, respectively. If not utilized, the credits begin to expire in 2040 and 2028 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2024, we had available orphan drug tax credits for federal purposes only of approximately $ 37.5 million. If not utilized, the orphan drug credits begin to expire in 2040. | text | 320.0 | monetaryItemType | text: <entity> 320.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we had net operating loss carryforwards, or NOLs, available to reduce state and foreign income taxes of approximately $ 320.0 million and $ 65.2 million, respectively. At December 31, 2024, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 23.2 million and $ 29.3 million, respectively. If not utilized, the credits begin to expire in 2040 and 2028 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2024, we had available orphan drug tax credits for federal purposes only of approximately $ 37.5 million. If not utilized, the orphan drug credits begin to expire in 2040. </context> | us-gaap:OperatingLossCarryforwards |
As of December 31, 2024, we had net operating loss carryforwards, or NOLs, available to reduce state and foreign income taxes of approximately $ 320.0 million and $ 65.2 million, respectively. At December 31, 2024, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 23.2 million and $ 29.3 million, respectively. If not utilized, the credits begin to expire in 2040 and 2028 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2024, we had available orphan drug tax credits for federal purposes only of approximately $ 37.5 million. If not utilized, the orphan drug credits begin to expire in 2040. | text | 65.2 | monetaryItemType | text: <entity> 65.2 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we had net operating loss carryforwards, or NOLs, available to reduce state and foreign income taxes of approximately $ 320.0 million and $ 65.2 million, respectively. At December 31, 2024, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 23.2 million and $ 29.3 million, respectively. If not utilized, the credits begin to expire in 2040 and 2028 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2024, we had available orphan drug tax credits for federal purposes only of approximately $ 37.5 million. If not utilized, the orphan drug credits begin to expire in 2040. </context> | us-gaap:OperatingLossCarryforwards |
As of December 31, 2024, we had net operating loss carryforwards, or NOLs, available to reduce state and foreign income taxes of approximately $ 320.0 million and $ 65.2 million, respectively. At December 31, 2024, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 23.2 million and $ 29.3 million, respectively. If not utilized, the credits begin to expire in 2040 and 2028 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2024, we had available orphan drug tax credits for federal purposes only of approximately $ 37.5 million. If not utilized, the orphan drug credits begin to expire in 2040. | text | 23.2 | monetaryItemType | text: <entity> 23.2 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, we had net operating loss carryforwards, or NOLs, available to reduce state and foreign income taxes of approximately $ 320.0 million and $ 65.2 million, respectively. At December 31, 2024, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 23.2 million and $ 29.3 million, respectively. If not utilized, the credits begin to expire in 2040 and 2028 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2024, we had available orphan drug tax credits for federal purposes only of approximately $ 37.5 million. If not utilized, the orphan drug credits begin to expire in 2040. </context> | us-gaap:TaxCreditCarryforwardAmount |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.